Table 1.
Demographic, disease and treatment characteristics of the study population
| All patients (n = 497) | RA patients (n = 248) | SpA patients (n = 249) | |
|---|---|---|---|
| Age, mean (SD) (range) years | 55.7 (13.0) (22–86) | 60.8 (12.4) (24–86) | 50.6 (11.6) (22–76) |
| Sex (% women) | 62.8 | 81.0 | 44.6 |
| Smoking at vaccination (%) | 17.4 | 19.0 | 15.7 |
| Disease duration mean (SD) (range) years | 14.9 (11.2) (0–48) | 15.9 (11.5) (0–48) | 13.8 (10.8) (0–45) |
| DAS28 (SD) (range) | 3.2 (1.2) (0–6.4) | 3.6 (1.1) (0.6-5.9) | 2.8 (1.2) (0–6.4) |
| DAS28 CRP at vaccination (0–10) | 2.7 (0.97) (0.96-5.6) | 2.9 (0.9) (0.96-4.9) | 2.5 (0.98) (0.96-5.6) |
| HAQ at vaccination (0–3) (range) | 0.7 (0.6) (0–3.0) | 0.9 (0.7) (0–3.0) | 0.5 (0.5) (0–2.13) |
| RF at vaccination (%) | ---- | 79.8 | ---- |
| Anti-CCP at vaccination (%) | ---- | 77.8 | ---- |
| HLA-B27 (%) | ---- | ---- | 47.8 |
| MTX at vaccination (%) | 51.1 | 69.4 | 33.0 |
| MTX + anti-TNF at vaccination (%) | 31.8 | 35.1 | 32.9 |
| Anti-TNF as monotherapy (%) | 34.0 | 30.6 | 32.9 |
| NSAIDs without other anti-rheumatic treatment (%) | 17.1 | 0 | 34.1 |
| Serious infection before vaccination (number of events) | 18 | 13 | 5 |
| Serious infection after vaccination (number of events) | 27 | 23 | 4 |
RA, rheumatoid arthritis; SpA, spondylarthropathy; DAS28, disease activity score using 28 joint counts; CRP, C-reactive protein; HAQ, health assessment questionnaire; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide; HLA-B27, human leukocyte antigen B27; MTX, methotrexate; anti-TNF, anti-tumor necrosis factor; NSAIDs, non-steroidal anti-inflammatory drugs.